Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations

OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare disease that is currently considered a low-grade neoplasm with metastatic potential and variable progression. Mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, have recently become a treatment option for LAM patient...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Bras Pneumol
Glavni autori: Freitas, Carolina Salim Gonçalves, Baldi, Bruno Guedes, Araújo, Mariana Sponholz, Heiden, Glaucia Itamaro, Kairalla, Ronaldo Adib, Carvalho, Carlos Roberto Ribeiro
Format: Artigo
Jezik:Inglês
Izdano: Sociedade Brasileira de Pneumologia e Tisiologia 2015
Teme:
Case Series
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4541764/
https://ncbi.nlm.nih.gov/pubmed/26176526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1590/S1806-37132015000004553
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items